When a conference is on, that’s a unique opportunity for getting your science field into the press. You’ve invested time and energy on getting top thought leaders together in place.
We can help you to make the most of it: from putting out a press release and getting the buzz up in the lead-up, to building a conference media room and even organising an outside broadcast on site.
We can also set up and manage conference media centres, with facilities for journalists and media briefings, and put together special media and public events and photo opportunities.
Melissa Little and her colleagues worked for six years to bring the world’s largest stem cell meeting to Melbourne this week.
What did she learn? What are the next big steps should we should be watching for in curing diseases and saving lives with stem cells?
Melissa can also talk about her own research at the Murdoch Children’s Research Institute. She’s made mini-kidneys that are a step towards stopping a silent killer, chronic kidney disease.
The International Society for Stem Cell Research 2018 Annual Meeting closes today. 2,500+ stem cell scientists from 53 countries heard from 150+ speakers.
Treating haemophilia and eye disease with gene therapy
Katherine High (USA) will report today on an FDA approved gene therapy for a form of blindness, and on a clinical trial in people with haemophilia. [continue reading…]
It’s Day 3 of the International Society for Stem Cell Research (ISSCR) 2018 Annual Meeting at the Melbourne Convention and Exhibition Centre: more than 2,500 stem cell scientists from 50 countries will hear from 150+ speakers, including:
Lab-grown mini-brains make new connections
Fred ‘Rusty’ Gage (USA) is making mini-brains from human stem cells in the lab. But in order for these new tissues to function, they need to become well-connected.
Fred is pioneering research to explore how transplanted human neural organoids (mini-organs) can mature into tissues with blood vessel and nerve connections. This work could lead to methods of replacing brain tissue lost to stroke or disease, and repairing spinal cords damaged by trauma.
20-23 June 2018 at the Melbourne Convention and Exhibition Centre
International Society for Stem Cell Research 2018 Annual Meeting: 2,500+ stem cell scientists from 50 countries will hear from 150+ speakers including:
Lab-grown mini-brains make new connections
Fred ‘Rusty’ Gage (USA) is making mini-brains from human stem cells in the lab. But in order for these new tissues to function, they need to become well-connected.
Fred is pioneering research to explore how transplanted human neural organoids (mini-organs) can mature into tissues with blood vessel and nerve connections. This work could lead to methods of replacing brain tissue lost to stroke or disease, and repairing spinal cords damaged by trauma.
Tracing blood back to its beginnings to tackle leukaemia
Right now, the stem cells in your bone marrow are making one billion new red blood cells per minute. Andrew Elefanty (Australia) is studying both embryonic stem cells and more specialised blood-forming stem cells to reveal how our body makes blood and what leads to leukaemia and other blood diseases. He will reveal his team’s latest insights. [continue reading…]
New York, USA; June 20, 2018; and Melbourne, Australia; June 21, 2018:
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The results are being presented today at the 2018 annual meeting of the International Society for Stem Cell Research (ISSCR), being held in Melbourne from June 20-23.
The open-label Phase 3 trial enrolled 55 children with steroid-refractory aGVHD (aged between two months and 17 years) in 32 sites across the United States, with 89% of patients suffering from the most severe form, grade C/D aGVHD. The trial was performed under an United States Food and Drug Administration (FDA) Investigational New Drug Application (NCT#02336230). [continue reading…]
It’s Day 2 of the International Society for Stem Cell Research (ISSCR) 2018 Annual Meeting at the Melbourne Convention and Exhibition Centre: more than 2,500 stem cell scientists from 50 countries will hear from 150+ speakers, including:
Treating type 1 diabetes with stem cells
A Harvard team has shown they can control glucose levels in mice using a transplant of insulin-producing cells made from human stem cells. Doug Melton presents his research today.
His effort to fight diabetes involves a 30-person lab at Harvard and a start-up company, Semma Therapeutics, which he named after his children. His son Sam and daughter Emma both have type 1 diabetes. [continue reading…]
Could you regrow an arm or a leg? Salamanders can.
Should you be allowed to try unapproved treatments without the FDA tick when you’re terminally ill? President Trump says yes.
20-23 June 2018 at the Melbourne Convention and Exhibition Centre
International Society for Stem Cell Research 2018 Annual Meeting: more than 2,500 stem cell scientists from 50 countries will hear from 150+ speakers, including:
Taking stem cell science from the lab to the clinic, and what’s wrong with the US ‘right to try’ legislation—Roger Barker, UK
Could you regrow an arm or a leg? Salamanders can.
Should you be allowed to try unapproved treatments—without the FDA tick—when you’re terminally ill? President Trump says yes.
It’s Day 1 of the International Society for Stem Cell Research (ISSCR) 2018 Annual Meeting at the Melbourne Convention and Exhibition Centre: more than 2,500 stem cell scientists from 50 countries will hear from 150+ speakers, including:
Taking stem cell science from the lab to the clinic, and what’s wrong with the US ‘right to try’ legislation—Roger Barker, UK
ISSCR is concerned about ‘right to try’ legislation just signed into law in the US, which allows terminally ill patients to try risky, unproven treatments without regulation or oversight. Doctors and scientists are alarmed. They say current compassionate use provisions allow access.
Mending broken hearts and burnt eyes, and much more
Stem cells are saving lives today—through bone marrow and cord blood transplants
There are trials making new skin, restoring sight, treating diabetes, repairing the brain
But we’ll also hear of the dangers of risky treatments, snake oil merchants, and new Australian and US regulations.
More than 2,500 stem cell scientists from 50 countries are in Melbourne this week for the massive International Society for Stem Cell Research 2018 Annual Meeting. It’s taking place from 20-23 June at the Melbourne Convention and Exhibition Centre. Here are some highlights and we’ll have daily alerts for you with more people and ideas through the week.
Media are welcome.
Developing a stem cell product to cure blindness from burning—Michele De Luca and Graziella Pellegrini, Italy
Italian innovators Graziella Pellegrini and Michele De Luca have seen their work lead to patients regaining eyesight after 20 years of blindness. And it’s led to the world’s first non-blood-related commercial stem cell therapy.
Images may be used by the media, provided credit is given to the photographer.
For hi-res versions please click on the photo and then right click to download the file.
Human forebrain neurons derived from induced pluripotent stem cells and infected with Australian bat lyssavirus, a type of rabies found in Australian bats. (Credit: Vinod Sundaramoorthy / ASSCR)
20-23 JUNE 2018 AT THE MELBOURNE CONVENTION AND EXHIBITION CENTRE
Stem cells are saving lives today—through bone marrow and cord blood transplants
We’ll hear about trials making new skin, restoring sight, treating diabetes, repairing the brain
But we’ll also hear of the dangers of risky treatments, snake oil merchants, and new US regulations
Australia is tightening regulations in an effort to reign in rogue stem cell clinics.
The US is also cracking down on clinics marketing unproven treatments to patients. But ‘right to try’ laws there allow seriously ill patients to try experimental therapies without regulation or oversight. Doctors and scientists are alarmed.
More than 2,500 stem cell scientists from 50 countries are in Melbourne next week for the massive International Society for Stem Cell Research 2018 Annual Meeting. They will hear sound science from 150+ speakers, including: [continue reading…]
We are a specialist science communication and public relations business. We help you communicate complex ideas simply to the public, media, government, and industry; on any platform from social media, to media, pitches, publications, events and conferences.
Our team are all working from home and can consult/train/mentor/write via phone, Zoom, Teams, Skype etc
Upcoming training sessions
Media and communication masterclass:
Practice interviews. Key messages. Tricky questions. How to ensure your research is reported accurately.
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
Anonymous - Sydney Jan 2020
Science In Public
2020-01-28T15:04:28+11:00
Anonymous - Sydney Jan 2020
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
Shwathy Ramesh
Science In Public
2020-02-24T09:29:55+11:00
Shwathy Ramesh
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
When will stem cells save more lives?
When will stem cells save more lives?
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The results are being presented today at the 2018 annual meeting of the International Society for Stem Cell Research (ISSCR), being held in Melbourne from June 20-23.
